INBS Stock — Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (INBS)

Updated October 16, 2026.

INBS is a Stock. Total return is -100.0% over the past 5.8 years, 224.2 points behind SPY at 124.2%.

Intelligent Bio Solutions Inc. is a medical technology company developing non-invasive testing and screening solutions, including an intelligent fingerprinting drug screening system that analyzes fingerprint sweat to detect drug abuse, along with biosensor platforms. The company operates internationally with a presence in the Asia Pacific, United States, and United Kingdom regions. This stock does not currently have an established distribution schedule.

INBS performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 5.8 years, 224.2 points behind SPY at 124.2%. Over the past year its total return — price change plus distributions reinvested — is -85.4%. Its deepest 1-year drawdown was 92.0%.

INBS key facts

Asset type

Stock

Asset class

Equity

Inception date

12/23/2020

Distribution frequency

None

Last close

$1.50 (as of 2026-10-16)

Market cap

$4,975,204

Average volume

23526.0

Beta

4.248

Payout ratio

0.0%

Forward P/E

4.1143

EPS

$-8.44

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

INBS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 92.0%.

Who may consider INBS — and who may not

It is a weaker fit for investors who need monthly cash flow (INBS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on INBS

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions